Technivie® (ombitasvir/paritaprevir/ritonavir) – Expanded indication
February 27, 2017 – The FDA approved AbbVie’s Technivie (ombitasvir/paritaprevir/ritonavir), in combination with ribavirin for the treatment of patients with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.
Top